Hericene A

Hericene A at a Glance

Hericene A is an aromatic compound from the fruiting body of lion’s mane, distinct from the better-known hericenones and erinacines that dominate discussion of the mushroom.

Its notable finding is recent and specific: a 2023 study reported pan-neurotrophic activity — promoting neuronal growth through a mechanism independent of nerve growth factor, which is the pathway lion’s mane is usually credited with.

That would make it a separate route to the same effect, and it rests on a single study.

What It's Used For

Hericene A is an aromatic hericerin derivative (of the isohericerin family) found in the fruiting body of lion’s mane (Hericium erinaceus). It is a distinct, less-studied molecule from the two better-known neuroactive groups of the mushroom: the hericenones (fruiting-body NGF-synthesis stimulators) and the erinacines (mycelium-specific cyathane diterpenoids). Its entire notable profile rests on essentially one study — a 2023 report that hericene A drives a neurotrophic response and improves memory in mice — and the load-bearing caveat is that lion’s mane’s human cognitive data (small trials in mild cognitive impairment) belongs to the whole extract/mycelium, not to this isolated constituent.

A single-study neurotrophic signal:hericene A promoted potent neurite outgrowth and a pan-neurotrophic response in hippocampal neurons converging on ERK1/2, and a hericene-A-containing extract improved recognition/spatial memory in mice ^{1Reference 1Martínez-Mármol R et al. · 2023Hericerin derivatives activate a pan-neurotrophic pathway in central hippocampal neurons converging on ERK1/2 signalling to enhance spatial memoryView study →}.

A distinctive mechanistic note:the effect was reported BDNF-independent — neurotrophic-pathway activity distinct from classical BDNF/TrkB ligand signaling, and different from the hericenones’ NGF-synthesis route ^{1Reference 1Martínez-Mármol R et al. · 2023Hericerin derivatives activate a pan-neurotrophic pathway in central hippocampal neurons converging on ERK1/2 signalling to enhance spatial memoryView study →}.

The honest headline:one research group, one publication; no replication, no human isolate data, no pharmacokinetics — and the memory readout used a whole extract, not the purified compound ^{1Reference 1Martínez-Mármol R et al. · 2023Hericerin derivatives activate a pan-neurotrophic pathway in central hippocampal neurons converging on ERK1/2 signalling to enhance spatial memoryView study →}.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Essentially one study for the isolate, so scores stay low by design.

Mechanisms

Target / pathway	Effect	Relevant to
Pan-neurotrophic signaling → ERK1/2 (MAPK)	activation; drives neurite outgrowth in hippocampal neurons	neurotrophic / cognitive
Neurotrophic response — BDNF-independent	pathway activation without requiring BDNF; distinct from canonical BDNF/TrkB ligand action	neurotrophic / cognitive
Neurite outgrowth / memory	↑ length and branching in vitro; behavioral memory improvement in mice (whole extract)	cognitive / memory

Honest mechanism note: the verified finding centers on a pan-neurotrophic pathway convergent on ERK1/2 and is explicitly BDNF-independent — describe it that way rather than asserting a clean canonical TrkB-BDNF agonism. Contrast with the hericenones (NGF-synthesis stimulation) and erinacines (NGF-stimulating cyathane diterpenoids).

Pharmacokinetics

There is no data. No absorption, distribution, metabolism, excretion, bioavailability or brain-penetration parameter has been measured for isolated hericene A in any species. The mouse memory readout used an oral whole extract — implying some functionally relevant CNS exposure — but no PK parameters were determined.

Clinical trials

There are no human trials of hericene A. Small human cognitive trials of lion’s mane (e.g. in mild cognitive impairment, and an erinacine-A-enriched mycelium pilot in mild Alzheimer’s) used whole fruiting-body extract or mycelium, not hericene A — those results cannot be attributed to this constituent.

Completed	Planned	Terminated	Preclinical
—(none, isolate)	—	—	Thin(one study)

Last checked: July 2026.

Toxicity & Safety

Hericene A’s reassuring rating comes entirely from its source — a widely eaten mushroom — and not from any testing of the isolate itself, which has never undergone toxicology.

Safety at a Glance

Low / no toxicityAllergy risk

Good dietary track record. It occurs in lion’s mane, a widely consumed edible mushroom with a long history of use and good general tolerability.
Avoid the concentrated isolate in pregnancy and lactation. Untested.
The purified isolate has never been tested. No LD50, genotoxicity or organ-toxicity data; the low rating reflects the whole-food context.
Rare hypersensitivity reported. Idiosyncratic dermatitis and respiratory reactions to lion’s-mane whole products.

Full Safety & Interactions Detail

Hericene A carries a low flag by origin: it occurs in Hericium erinaceus, a widely consumed edible mushroom with a long dietary history and good general tolerability. However, the purified isolate has never undergone toxicology — no LD50, genotoxicity or organ-toxicity data — so the low rating reflects the whole-food context, not isolate-specific testing. Rare idiosyncratic dermatitis/respiratory hypersensitivity is reported for lion’s-mane whole products.

Dosage

There is no established dose for hericene A. No human or defined preclinical dose exists for the isolate, and content in fruiting-body products varies widely with strain, substrate and extraction and is not standardized. Any dosing guidance should reference whole lion’s-mane extract, not this constituent.

References

Martínez-Mármol R, et al. (2023). Hericerin derivatives activate a pan-neurotrophic pathway in central hippocampal neurons converging on ERK1/2 signalling to enhance spatial memory. Journal of Neurochemistry. https://pubmed.ncbi.nlm.nih.gov/36660878/